Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 5, 2013, Pages 581-587

  Bateman, Eric D ^a   Kornmann, Oliver ^b   Ambery, Claire ^c   Norris, Virginia ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b IKF Pneumologie Frankfurt   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bi functional molecule; COPD; MABA

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GSK 961081; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREMOR; XEROSTOMIA;

BI-FUNCTIONAL MOLECULE; COPD; MABA;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; CARBAMATES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SCOPOLAMINE DERIVATIVES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882590787     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.03.015     Document Type: Article

References (28)

1. The global initiative for chronic obstructive lung disease (GOLD) revised 2011, http://www.goldcopd.com.
2. Celli B.R., MacNee W., Agusti A., Anzueto A., Berg B., Buist A.S., et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
3. 2-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002, 4:CD001495.
4. Dahl R., Greefhorst L.A., Nowak D., Nonikov V., Byrne A.M., Thomson M.H., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784.
5. Hanania N.A., Kalberg C., Yates J., Emmett A., Horstman D., Knobil K. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 2005, 18:19-22.
6. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., et al. Along-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224.
7. Liesker J.J.W., Wijkstra P.J., Ten Hacken N.H.T., Koëter G.H., Postma D.S., Kerstjens H.A.M. Asystematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002, 121:597-606.
8. Man W.D., Mustfa N., Nikoletou D., Kaul S., Hart N., Rafferty G.F., et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004, 59:471-476.
9. O'Donnell D.E., Fluge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840.
10. Sin D.D., McAlister F.A., Man S.F., Anthonisen N.R. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003, 290:2301-2312.
11. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper J.A., Korducki L., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005, 143:317-326.
12. Mahler D.A., Donohue J.F., Barbee R.A., Goldman M.D., Gross N.J., Wisniewski M.E., et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115:957-965.
13. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002, 19:209-216.
14. 2-agonist molecules for the treatment of chronic obstructive pulmonary disease. Future Med Chem 2011, 3:1585-1605.
15. 2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23:257-267.
16. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Verhaert J., Disse B., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26:214-222.
17. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Zaagsma J., Mueller A., et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010, 104:995-1004.
18. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
19. Terzano C., Petroianni A., Conti V., Ceccarelli D., Graziani E., Sanduzzi A., et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008, 102:1701-1707.
20. van Noord J.A., Buhl R., LaForce C., Martin C., Jones F., Dolker M., et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010, 65:1086-1091.
21. 2-adrenergic agonist activity. Am J Respir Crit Care Med 2009, 179:A4552.
22. 2-adrenergic agonist with potent and sustained invivo bronchodilator activity in guinea pigs. Am J Respir Crit Care Med 2009, 179:A6195.
23. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
24. Tashkin D.P., Donohue J.F., Mahler D.A., Huang H., Goodwin E., Schaefer K., et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009, 103:516-524.
25. Cazzola M., Andò F., Santus P., Ruggeri P., Di Marco F., Sanduzzi A., et al. Apilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007, 20:556-561.
26. Singh D., Brooks J., Hagan G., Cahn A., O'Connor B.J. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008, 63:592-598.
27. Short P.M., Williamson P.A., Elder D.H.J., Lipworth S.I.W., Schembri S., Lipworth B.J. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest January 2012, 141:81-86.
28. Hanania N.A., Celli B.R., Donohue J.F., Martin U.J. Bronchodilator reversibility in COPD. Chest 2011, 140(4):1055-1063.